Evidence map›Paper›PMID 40167409›Full record

ArticleMayo Clinic proceedings2025

Proteomic Profile of Ischemic Heart Disease in Heart Failure: A Community Study.

Kayode O Kuku, Maryam Hashemian, Jungnam Joo, Joseph J Shearer, Carolina G Downie, Mohit Aggarwal, Suzette J Bielinski, Véronique L Roger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kayode O KukuHeart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Maryam HashemianHeart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Jungnam JooOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Joseph J ShearerHeart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Carolina G DownieHeart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Mohit AggarwalLaboratory for Cardiovascular Epidemiology and Genomics, Population Sciences Branch, Division of Intramural Research National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Suzette J BielinskiDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Véronique L RogerHeart Disease Phenomics Laboratory, Epidemiology and Community Health Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address: veronique.roger@nih.gov.

Funding

Heart failure proteomics: an epidemiology studyZIAHL006279 · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2025 to 2025
$2.6M
Intramural NIH HHS ZIA HL006260Intramural NIH HHS ZIA HL006279NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

objectiveTo investigate the clinical characteristics, outcomes, and proteomic profiles of prevalent ischemic heart disease (IHD) in heart failure (HF) in a clinically phenotyped cohort.

methodsWe studied an HF community cohort (N=1351) enrolled between September 10, 2003, and September 18, 2012, with linked medical records and measured 7289 plasma protein targets using an aptamer-based assay. Ischemic heart disease was defined by prior myocardial infarction, angiographic coronary disease, or revascularization. Cause-specific hazards model was used to test the association between IHD status and cardiovascular (CV) mortality while considering the interaction by ejection fraction (EF) group. Linear regression adjusting for age, sex, and estimated glomerular filtration rate with multiple testing correction was used to evaluate the cross-sectional association of proteins with IHD status and with CV risk factors.

resultsThere were 678 patients with IHD (median age, 78 years [interquartile range, 69 to 84 years]; 271 [40%] female). The association between IHD status and CV mortality was markedly influenced by EF (P

conclusionThese data suggest that unique proteomic profiles reveal biologic signatures of IHD in HF, emphasizing the importance of molecular data in classifying HF phenotypes. In addition, our findings underscore the prognostic significance of IHD in HF with reduced EF.

Indexed as

Heart FailureMyocardial IschemiaProteomicsAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleStroke Volume

Identifiers

PMID40167409
PMCPMC12226227

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.